ArticleJCO precision oncology2026

Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.

Marija Balic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.